Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (May 2016)

36 slides from Enumeral Biomedical's investor presentation, May 13, 2016

  1. Slide 1: Enumeral Overview

    Enumeral Overview May 2016 : | e ENUSERAL

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD - LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY . THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF

  3. Slide 3: Enumeral Overview

    Enumeral Overview • Potential first - in - class non - competitive PD - 1 antagonist – Novel mechanism in a proven immuno - oncology pathway • Clinical significance: – Potential to treat failure and relapse due to differentiated mechanism: drives both arms of the immune system – Not all patients ben

  4. Slide 4: Agenda

    Agenda 1. Optimizing Drugs Against PD - 1: Lessons Learned 2. ENUM 244C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. Opportunity 4. Pipeline, Platform, and Collaborators 5. Management and Directors 4

  5. Slide 5: Lessons Learned: Current Therapy

    Lessons Learned: Current PD - 1 Therapy 5 Figure adapted from Johannes B. Huppa & Mark M. Davis, Nature Reviews Immunology 3, 973 - 983 (December 2003). • The PD - 1 checkpoint negatively regulates T cell activity à current drugs do not show does - responsive pharmacology • Cancer cells can ‘turn of

  6. Slide 6: And, T cells do not act alone

    And, T cells do not act alone … 6 • Multiple cell types participate in anti - tumor immune responses Oncology Meets Immunology: The Cancer - Immunity Cycle ; Daniel S. Chen, Ira Mellman Immunity; Volume 39, Issue 1, Pages 1 - 10 (July 2013) • Dendritic, natural killer, and other cells of the innate

  7. Slide 7: Agenda

    Agenda 1. Optimizing Drugs Against PD - 1: Lessons Learned 2. ENUM 244C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. Opportunity 4. Pipeline, Platform, and Collaborators 5. Management and Directors 7

  8. Slide 8: Enumeral Lead Program: 244C8

    Enumeral Lead Program: 244C8 • Potential to drive coordinated activation of both innate and adaptive immunity through novel mechanism in a proven immuno - oncology pathway • May decrease tumor’s ability to escape immune control à both arms of immune system activated • Potential for treatment of refr

  9. Slide 9: Enumeral Lead Compounds

    Enumeral Lead Compounds • Enumeral antibody discovery results in broad diversity of novel functional antibodies 9 Dendrogram of ENUM anti - PD - 1 antibodies: Heavy chain AA sequences; 159 sequences clustering into 28 families of antibodies Conventional MOA Comparable pharmacologic properties to app

  10. Slide 10: Enumeral's Novel Non-Competitive PD-1 Antagonist 244C8

    Enumeral’s Novel Non - Competitive PD - 1 Antagonist 244C8: Biology Of PD - 1 Blockade Depends On The Antibody 10 244C8 Antibody shows enhanced in vitro T cell activation IFNg secretion (relative to control) N = 5 repetitions for each candidate/condition • PBMC - based assay to determine mAb’s abili

  11. Slide 11: 244C8 Inhibits Tumor Growth in Mouse Model

    244C8 Inhibits Tumor Growth in Mouse Model with Re - constituted Human T Cell Lineages 11 Tumor size (mm 3 ) 0 3 6 10 13 17 20 24 28 0 250 500 750 1000 1250 Group 1: Vehicle Group 2: 388D4 Group 3: 244C8 Group 4: Pembrolizumab Day 95% confidence interval plotted Studies performed by The Jackson Labo

  12. Slide 12: D - H C + L C D - H C + L C

    D 4 - H C 3 + L C 1 D 4 - H C 1 + L C 3 D 4 - H C 3 + L C 3 C 8 - H C 1 + L C 1 C 8 - H C 1 + L C 3 C 8 - H C 2 + L C 1 N i v o - I g G 4 h I g G 4 - H C A 2 4 7 0 5000 10000 MLR Donor 337+23 (IFNy) I F N y ( p g / m l ) 10 ug/ml 1 ug/ml 0.1 ug/ml 0.01 ug/ml Antibody concentration Antibody concentra

  13. Slide 13: 244C8 Elicits Cytokine Signature Consistent with Activation of Innate Immunity

    244C8 Elicits Cytokine Signature Consistent with Activation of Innate Immunity 13 Ex vivo cytokine production in NSCLC tumor biopsy consistent with focal activation of both innate & adaptive anti - tumor immunity B i o e g e n d I g G 4 ( 1 0 u g / m L ) 3 8 8 D 4 - 2 ( 1 0 u g / m L ) 2 4 4 C 8 - 2

  14. Slide 14: 244C8 does not activate Th1 cytokine production in the absence of TCR stimulation

    244C8 does not activate Th1 cytokine production in the absence of TCR stimulation IFN? donor 20 pg/mL PBS hIgG4 (20 µg/mL)C8 (20 µg/mL)D4 (20 µg/mL)KLH (20 µg/mL)LPS (2 µg/mL) 0 100 200 300 400 500 IL-6 donor 20 pg/mL PBS hIgG4 (20 µg/mL)C8 (20 µg/mL)D4 (20 µg/mL)KLH (20 µg/mL)LPS (2 µg/mL) 0 50000

  15. Slide 15: 244C8 Mechanism is CD40L-Dependent

    244C8 Mechanism is CD40L - Dependent: Consistent with Linkage of Adaptive and Innate Immunity 15 Kambayashi & Laufer NRI 2014 CMV recall assay with C8 PD1 blockade ± CD40L blockade These data suggest C8 - based PD1 blockade potentiates both T cell activation ( IFN g ) & APC (IL - 12) activation

  16. Slide 16: 244C8 Acts via Non-Competitive Mechanism

    244C8 Acts via Non - Competitive Mechanism 16 PD - L1 engagement results in T cell inhibition Current anti - PD1 agents disrupt PD - L1 binding to PD - 1 Hypothesis: ENUM anti - PD1: novel epitope and PD - L1 independent binding; IL - 2R autocrine activation à enhanced T cell activation ENUM antibod

  17. Slide 17: Cognate interactions between T cells and myeloid cells induce IL-12

    Cognate interactions between T cells and myeloid cells induce IL - 12 and regulate IFN - g expression 17 Hypothesis: 244C8 ‘locks’ PD - 1 and PD - L1 into a ternary complex that is sterically excluded from TCR microclusters in the synapse, promoting T cell activation and CD40L activity; competitive

  18. Slide 18: Enumeral's Lead Antibody May Have Multiple Actions in the Cancer Immunity Cycle

    Enumeral’s Lead Antibody May Have Multiple Actions in the Cancer Immunity Cycle 18 Source: Oncology Meets Immunology: The Cancer - Immunity Cycle ; Daniel S. Chen, Ira Mellman Immunity; Volume 39, Issue 1, Pages 1 - 10 (July 2013) • First - generation drugs optimized for effects on T cells* à but T

  19. Slide 19: Agenda

    Agenda 1. Optimizing Drugs Against PD - 1: Lessons Learned 2. ENUM 244C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. Opportunity 4. Pipeline, Platform, and Collaborators 5. Management and Directors 19

  20. Slide 20: Not All Patients Are Benefiting

    Not All Patients Are Benefiting 20 Non responders Responders Value to payors if new products treat refractory and relapse patients Estimated sales for checkpoint blockers in 2020 $27 billion per year* (Estimate only for PD - 1/PD - L1 class ) *Cowen and Company **Bristol Myers Squibb, Merck, Amgen S

  21. Slide 21: Limitations of 1st Generation Inhibitors

    Limitations of 1 st Generation PD - 1 Inhibitors PD - 1 blockade through disrupting the PD - L1 interaction may not be the whole story • In the approved indications, response rates are 20% - 30% • Ability to predict responders based on PD - 1 or PDL - 1 expression is disappointing • Ability to predi

  22. Slide 22: Commercial Opportunity Lead by Antibodies

    Commercial Opportunity Lead by Antibodies 22 Figure and text adapted from: http://www.nature.com/nrd/journal/vaop/ncurrent/full/nrd.2015.35.html *As of January 2015, reported revenues were ~$20M for Provenge ; no revenues reported by Valeant which acquired Provenge T cell therapies; ~$0 revenue*; Ef

  23. Slide 23: Agenda

    Agenda 1. Optimizing Drugs Against PD - 1: Lessons Learned 2. ENUM 244C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. Opportunity 4. Pipeline, Platform, and Collaborators 5. Management and Directors 23

  24. Slide 24: Enumeral Pipeline

    Enumeral Pipeline 24 ENUM 244C8 • Novel non - competitive mechanism of binding leads to enhanced activity in vitro • Binding: differentiated epitope • Novel composition of matter • Potential mechanism of action through coordinated activation of adaptive and innate immunity TIM - 3 • Broad diversity

  25. Slide 25: TIM-3 Program Diversity Supports Development of Differentiated Candidates

    TIM - 3 Program Diversity Supports Development of Differentiated Candidates 25 *Based on ENUM evaluation of published literature Dendrogram showing bioinformatics analysis of Vh amino acid sequence among selected ENUM anti - TIM - 3 antibodies and known published antibodies. • TIM - 3 target complex

  26. Slide 26: ENUM Anti-TIM3 Antibody Activates Blockade-Refractory NSCLC TILs Ex Vivo

    ENUM Anti - TIM3 Antibody Activates PD - 1 Blockade - Refractory NSCLC TILs Ex Vivo 26 NSCLC 22 TILs do not respond to PD - 1 blockade ex vivo h I g G 4 ( 1 0 u g / m L ) E N U M C 8 ( 1 0 u g / m L ) 0 5000 10000 15000 I F N - ? ( p g / m L ) Isotype control m I g G 1 k ( 1 u g / m L ) T I M - 3 #

  27. Slide 27: Other Enumeral Pipeline Programs

    Other Enumeral Pipeline Programs BMS Immutep 27 GSK • ENUM LAG - 3 Antibodies To - Date: Broad Diversity – 102 Sequences – 40 Families – Encompass known published antibody space* • Other Screening Programs: – TIGIT – VISTA – OX40 – Others not disclosed Dendrogram showing bioinformatics analysis of V

  28. Slide 28: Translational Cancer Biology Platform Drives Pipeline

    Translational Cancer Biology Platform Drives Pipeline 28 Patient biopsy + Drug candidates Enables target validation, screening and selection of therapeutic candidates and testing potential combinations ex vivo + Patient - centric immune profiling of antibody modulation of cytokine secretion and rece

  29. Slide 29: Proprietary Platform Drives Discovery and Development Advantage

    Proprietary Platform Drives Discovery and Development Advantage 29 84,672 50µm microwells • Proprietary broadly enabling “Immune system on a chip” platform • Immuno - oncology still a “black box” – Requires mechanistically differentiated assets for entry – Requires translational biology insights to

  30. Slide 30: Strong Intellectual Property Position

    Strong Intellectual Property Position • Exclusive worldwide license with MIT/Harvard for platform technology – 8 issued patents in US and 41 issued in international jurisdictions – 17 pending patent applications (US & International) • Patents covering compositions of matter and methods – Application

  31. Slide 31: Collaborators Provide External Recognition of Differentiated Approach

    Collaborators Provide External Recognition of Differentiated Approach • MERCK : collaboration with a leading immuno - oncology pharmaceutical company – Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer tissues to identify functional cellular response

  32. Slide 32: Strategic Collaboration with MD Anderson Cancer Center

    Strategic Collaboration with MD Anderson Cancer Center • Goal to Discover and Develop Novel Antibodies Against Specified Immunotherapy Targets – Utilizes Enumeral’s antibody discovery and patient - centric immune profiling platform – Leverages MD Anderson’s preclinical and development expertise and

  33. Slide 33: Agenda

    Agenda 1. Optimizing Drugs Against PD - 1: Lessons Learned 2. ENUM 244C8 – A Differentiated Anti - PD - 1 Antibody That Drives Adaptive and Innate Immune Cell Activation 3. Opportunity 4. Pipeline, Platform, and Collaborators 5. Management and Directors 33

  34. Slide 34: Experienced Leadership Team

    Experienced Leadership Team 34 John J. Rydzewski Executive Chairman, Co - Founder, Director Arthur H. Tinkelenberg, Ph.D. President & CEO, Co - Founder, Director Cokey Nguyen, Ph.D. Vice President, Research & Development Isabel Chiu, Ph.D. Vice President, Translational & Clinical Sciences Kevin G. S

  35. Slide 35: Non-Management Directors

    Non - Management Directors 35 Barry Buckland, Ph.D. Co - Founder; Chairman, Scientific Advisory Board Robert J. Easton Allan Rothstein Paul J. Sekhri Robert L. Van Nostrand

  36. Slide 36: THE POWER of HUMAN

    THE POWER of HUMAN™

Enumeral Biomedical Holdings — Investor Presentation (May 2016) on 6ix